Are you curious about how CAR T-cell therapy is revolutionizing cancer treatment? With the demand for effective therapies skyrocketing, finding the right manufacturer for CAR T-cell products can feel overwhelming. The quality of these therapies hinges on the expertise of the supplier, making it crucial to choose wisely. Top manufacturers not only ensure superior product quality but also streamline the production process, reducing wait times for patients in need.

Imagine being part of a solution that saves lives, while partnering with the best in the industry. Ready to discover the leading CAR T-cell manufacturing companies and what sets them apart? Dive into our article to explore the factories that are shaping the future of cancer treatment!

Related Video

Eight CAR-T cell therapy companies you should know about – Labiotech.eu

Product Details:
Allogene Therapeutics develops allogeneic CAR-T cell therapy products, with the most advanced candidate being cema-cel, an anti-CD19 CAR T therapy in phase 2 trials for large B-cell lymphoma.

Technical Parameters:
– cema-cel targets CD19 antigen
– gene editing to mitigate side effects
– phase 2 trial for large B-cell lymphoma
– phase 1 trials for chronic lymphocytic leukemia and multiple myeloma

Application Scenarios:
– treatment of large B-cell lymphoma
– treatment of relapsed/refractory chronic lymphocytic leukemia
– treatment of multiple myeloma

Pros:
– uses T cells from healthy donors, potentially reducing wait times
– gene editing to reduce side effects
– target-specific approach to cancer treatment

Cons:
– halted two phase 2 trials to shift focus
– still in clinical trial phases, not yet widely available

Top 30 CAR-T startups (May 2025) – Medical Startups

Product Details:
CAR T-cell therapy – a form of immunotherapy that uses specially altered T cells to fight cancer.

Technical Parameters:
– Utilizes advanced cell programming CAR-T and manufacturing technologies
– Develops targeted lifesaving therapeutics using genome engineering
– Focus on adoptive immunotherapies for cancer
– Employs flexible therapeutic design to treat cancer

Application Scenarios:
– Treatment of haematological malignancies
– Treatment of solid tumors
– Targeting B cell-mediated autoimmune diseases
– Combating hard-to-treat cancers and autoimmune diseases

Pros:
– Innovative approach to cancer treatment using the body’s immune system
– Potential for personalized medicine through tailored therapies
– Ability to target specific cancer cells while sparing healthy cells
– Advancements in safety and efficacy for difficult-to-treat conditions

Cons:
– Potential serious side effects associated with CAR-T therapy
– High cost of development and treatment
– Limited availability of therapies in certain regions
– Complex manufacturing processes that can affect scalability

55 CAR-T Companies Worldwide – Biotech Careers

Top 5 CAR T Companies to Look for in 2024 – Roots Analysis

Product Details:
Gilead Sciences is developing various CAR-T cell therapies for the treatment of several types of cancers, including Yescarta® and Tecartus®. Yescarta® is approved for multiple indications including diffuse large B-cell lymphoma and acute lymphoblastic leukemia.

Technical Parameters:
– Yescarta® (CD19 CAR-T) – Approved for Diffuse Large B-Cell Lymphoma, Primary
– Tecartus® (Brexucabtagene Autoleucel) – Approved for Acute lymphoblastic
– KITE-585 (BCMA CAR-T) – Phase II for Multiple myeloma
– HuCAR-19 – Phase I for Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell leukemia

Application Scenarios:
– Treatment of relapsed or refractory cancers
– Management of diffuse large B-cell lymphoma
– Treatment of mantle cell lymphoma
– Clinical trials for various hematological malignancies

Pros:
– Ability to eradicate tumor cells with minimal treatment-related side effects
– Established sales and marketing network for oncology cell therapy
– Significant adoption of Yescarta in the US market
– Access to Yescarta on the NHS likely to drive sales growth in the EU

Cons:
– Manufacturing and supply chain challenges associated with autologous therapies
– Dependence on regulatory approvals for new therapies
– Limited to specific types of cancers currently

Top Companies in CAR T-cell Therapy (2024) – Aesthetics Advisor

Product Details:
AbbVie is co-developing CAR-T therapies with Calibr aimed at solid tumors and other cancers, utilizing a switchable CAR-T platform. Adaptimmune is developing SPEAR T-cells targeting multiple myeloma and non-small cell lung cancer. Agios is developing a BCMA CAR-T therapy for relapsed/refractory multiple myeloma. Alaunos is advancing CAR-T therapies for solid tumors using controlled IL-12 and Sleeping Beauty platforms. Allife is developing CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia.

Technical Parameters:
– Switchable CAR-T platform by Calibr
– SPEAR T-cell technology
– Controlled IL-12 platform
– Sleeping Beauty platform

Application Scenarios:
– Treatment of hematologic malignancies
– Targeting solid tumors
– Immunotherapy for multiple myeloma
– CAR-T therapy for acute lymphoblastic leukemia

Pros:
– Enhanced safety and versatility through switchable CAR-T technology
– Robust pipeline with multiple INDs open
– Potential for universal CAR-T treatments across various cancers
– Innovative non-viral gene transfer methods for rapid manufacturing

List of CAR T-Cell Companies Worldwide 2024 – OneDayMD

Product Details:
CAR-T therapies developed by various companies, including switchable CAR-T platforms, affinity-enhanced T-cell therapies, and CAR-NK therapies.

Technical Parameters:
– Switchable CAR-T platform by Calibr for enhanced safety and versatility.
– SPEAR T-cell platform by Adaptimmune for affinity-enhanced T-cell therapies.
– Non-viral Sleeping Beauty platform for rapid manufacturing of CAR+ T cells by
– CER-T technology by Anixa for a novel type of CAR-T.

Application Scenarios:
– Treatment of solid tumors and hematological malignancies.
– Immunotherapy for triple negative breast cancer (TNBC).
– Development of universal CAR-T treatments across various cancer types.
– Rapid manufacturing of genetically modified CAR+ T cells at point-of-care.

Pros:
– Innovative technologies aimed at improving safety and efficacy of CAR-T
– Collaboration with leading research institutions and companies.
– Potential for universal applications across multiple cancer types.
– Advanced AI integration for drug discovery and therapy development.

Cons:
– Complexity of engineering and manufacturing CAR-T therapies.
– Potential for off-target toxicity despite advanced technologies.
– High costs associated with development and commercialization.
– Regulatory challenges in bringing new therapies to market.

Global CAR T-Cell Therapy Company List – Mordor Intelligence

Product Details:
CAR T-cell therapies targeting hematological cancers and solid tumors, utilizing advanced technologies and innovative approaches.

Technical Parameters:
– Innovative CAR T-cell manufacturing processes
– Gene-editing techniques to enhance efficacy
– Proprietary platforms for allogeneic CAR T therapies
– High-quality reagents for CAR T-cell research

Application Scenarios:
– Treatment of hematological malignancies
– Targeting solid tumors with novel therapies
– Combination therapies integrated with existing oncology treatments
– Research and development in CAR T-cell technology

Pros:
– Strong pipeline of innovative therapies enhances market position
– Established expertise in cell therapy boosts credibility
– Pioneering developments in CAR T technology
– Focus on innovation and strategic partnerships for growth

Home – Allogene

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Product Details:
CAR-T therapies developed by various companies, including switchable CAR-T platforms and zCAR-T therapy for targeting different cancers.

Technical Parameters:
– Switchable CAR-T platform by Calibr for enhanced safety and efficacy.
– Modular design of zCAR-T therapy for adaptability to various cancer targets.
– Use of TALEN® gene editing technology in UCART19 by Allogene Therapeutics.

Application Scenarios:
– Treatment of solid tumors and hematological malignancies.
– Targeting triple negative breast cancer with CER-T technology.
– Utilizing NK cells for blood cancers and solid tumors.

Pros:
– Enhanced safety and versatility through switchable CAR-T technology.
– Modular design allows for ongoing adjustments to CAR-T cell function.
– Potential for universal CAR-T treatments across multiple cancer types.

Autolus – developing CAR T cell therapies for patients with cancer and …

Comparison Table

Frequently Asked Questions (FAQs)

What should I look for in a car T-cell manufacturing company?
When choosing a car T-cell manufacturer, consider their expertise in cell therapy, regulatory compliance, production capacity, and quality assurance processes. It’s also important to evaluate their track record with similar projects and their ability to scale production as needed.

How can I assess the quality of a car T-cell manufacturer?
To assess quality, check for certifications like ISO or GMP, review their manufacturing processes, and ask for references or case studies. You can also inquire about their quality control measures and any third-party audits they’ve undergone.

What are the typical costs associated with car T-cell manufacturing?
Costs can vary widely based on the complexity of the therapy, scale of production, and specific requirements. It’s best to request quotes from multiple manufacturers and understand what is included in the pricing, such as testing and regulatory support.

How important is regulatory compliance in choosing a manufacturer?
Regulatory compliance is crucial in the car T-cell industry. Ensure the manufacturer adheres to local and international regulations, as this impacts product safety and efficacy. A compliant manufacturer will have a robust quality management system in place.

What questions should I ask potential manufacturers during initial discussions?
During initial discussions, ask about their experience in car T-cell production, their capacity to meet your timeline, their approach to quality assurance, and how they handle regulatory submissions. Also, inquire about their flexibility in scaling production based on your needs.